Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of February 2022. The report, dated February 15, 2022, serves to distribute a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing does not provide comparative financial data or details on material changes versus prior periods. The document acts solely as a conduit for the attached press release.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risk factors, or contingencies are not detailed within the text of this Form 6-K. The content is limited to the submission of a press release dated February 15, 2022, signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) referenced in this filing for specific operational updates.
- Verify the company's latest audited financial statements in its most recent Form 20-F for revenue and liquidity data.
- Confirm the nature of the announcement made on February 15, 2022, as the filing itself contains no narrative details.